The Ratios of monounsaturated to saturated phosphatidyl cholines in lung adenocarcinoma microenvironment analyzed by Liquid Chromatography-Mass spectrometry and imaging Mass spectrometry

Yusuke Muranishi1, Toshihiko Sato2, Shinji Ito3, Junko Satoh3, Akihiko Yoshizawa4, Shigeyuki Tamari5, Yuichiro Ueda2,5,6, Yojiro Yutaka5,6, Toshi Menju5, Tatsuo Nakamura6 & Hiroshi Date5

Adenocarcinoma is the most common type of lung cancer, and can be classified into various histologic subtypes. However, little is known about the subtype-dependent variations in lipid metabolism processes. We performed dual lipidomic analyses using liquid chromatography–mass spectrometry (LC-MS) and matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI-IMS) to identify possible biomarkers to distinguish adenocarcinoma specimens from normal lung specimens, and to determine if there are any differences in lipid metabolism among the histologic subtypes (lepidic, acinar, papillary, micropapillary, solid, and mucinous). LC-MS was used to characterize the lipid profiles of lung adenocarcinoma and normal lung tissue, and MALDI-IMS analysis was performed to confirm the results with information on lipid localization within the lung. LC-MS analysis found significant differences in the relative abundances of phosphatidylcholine (PC)(16:0/16:0) (P = 0.0432) and sphingomyelin (SM)(42:2) (P < 0.0001) between adenocarcinoma and normal lung specimens. The ratios of PC(16:0/16:1)/PC(16:0/16:0), PC(16:0/18:1)/PC(16:0/16:0), and PC(16:0/18:1)/PC(16:0/18:0) were significantly higher in adenocarcinoma specimens (P = 0.02221, P = 0.0004, and P = 0.0215, respectively). MALDI-IMS analysis confirmed that these ratios were significantly higher in adenocarcinoma regions of the lung. The ratio of PC(16:0–18:1)/PC(16:0–18:0) was significantly lower in solid subtypes than in other subtypes (P = 0.0028). The monounsaturated/saturated PC ratios may have applications in adenocarcinoma diagnoses and subtyping.

Lung cancer is a major cause of cancer-related death throughout the world, and is often associated with a poor prognosis. Non-small-cell lung carcinomas account for approximately 85% of all lung cancers, and include adenocarcinomas, squamous cell carcinomas, and large-cell carcinomas1. Among these, adenocarcinomas represent the most common histologic variant of lung cancer.

1Department of Thoracic Surgery, Kyoto city Hospital, Kyoto, Japan. 2Department of General Thoracic Surgery, Breast and Pediatric Surgery, Fukuoka University School of Medicine, Fukuoka, Japan. 3Medical Research Support Center, Kyoto University Graduate School of Medicine, Kyoto, Japan. 4Department of Diagnostic Pathology, Kyoto University Graduate School of Medicine, Kyoto, Japan. 5Department of Thoracic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan. 6Department of Organ and Tissue Reconstruction, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan. Correspondence and requests for materials should be addressed to T.S. (email: toshisato@fukuoka-u.ac.jp)
In 2011, the International Association for the Study of Lung Cancer, the American Thoracic Society, and the European Respiratory Society collaboratively developed a classification scheme to standardize the diagnostic criteria for lung adenocarcinomas. In this system, lung adenocarcinomas are histologically classified into atypical adenomatous hyperplasia, adenocarcinomas in situ, minimally invasive adenocarcinomas, and invasive adenocarcinomas. Invasive adenocarcinomas are further divided into lepidic predominant, papillary predominant, acinar predominant, micropapillary predominant, solid predominant, invasive mucinous, and colloid/fetal/enteric predominant subtypes (Supplementary Table 1). These classifications have demonstrated good correlations with pathological malignancy and patient prognoses.

The metabolic processes of cancer have been extensively investigated. For example, recent studies have reported on the relationship between tumour progression and lipid metabolism. In addition, the expression of monounsaturated lipids has been found to be significantly higher than that of saturated lipids in various forms of cancer, including lung cancer. Several types of phospholipids have therefore been proposed as candidate biomarkers for lung cancer.

However, no reports in the existing literature have described lipid metabolism in lung adenocarcinoma according to the different histologic subtypes. We hypothesized that the different subtypes would have dissimilar lipid metabolic processes due to their variations in prognoses, pathological malignancy, and pathological findings. The aim of this study was to identify a distinct biomarker that can be used to differentiate adenocarcinoma from normal lung tissue. We also investigated if the different adenocarcinoma subtypes have distinctive phospholipid profiles.

In this study, we conducted a comprehensive investigation of the lipid profiles of lung adenocarcinoma and normal lung specimens using liquid chromatography–MS (LC-MS). These results were revaluated and confirmed using matrix-assisted laser desorption/ionization imaging MS (MALDI-IMS) supplemented with information on the lung localization of each lipid.

**Results**

**Patient characteristics.** The clinicopathological features of the patients are shown in Table 1. Samples from Patients 1 to 6 were subjected to both LC-MS and MALDI-IMS analyses. The majority of patients presented with Stage I tumours. Solid tumours (observed in 8 cases) were the most common of all subtypes. This was followed by papillary (7 cases), invasive mucinous (3 cases), acinar (3 cases), micropapillary (2 cases), and lepidic (2 cases) subtypes.

**LC-MS analysis results.** The S-plot of the orthogonal projections to latent structures discriminant analysis (OPLS-DA) revealed abundant ions at m/z 782.57 and m/z 760.58 in the adenocarcinoma specimens, whereas ions at m/z 734.57 and m/z 813.68 were more abundant in the normal lung specimens (Fig. 1A). We show the scores plot for OPLS-DA (Fig. 1B). Progenesis QI software predicted that these ions are derived from lipid species that are generally abundant in lung specimens. We show the top four variable importance in projection (VIP) scores of the OPLS-DA and the corresponding m/z (Table 2). The scores were calculated by EZinfo software (Waters). The highest VIP score was 23.9762 (for the ion with m/z 734.568 and retention time 8.23 min), followed by 19.7024 (m/z of 813.68 and retention time 13.51 min), 15.1571 (m/z of 760.58 and retention time 8.51 min) and 14.1025 (m/z of 782.56 and retention time 6.66 min). We further examined these lipid species through authentic MS/MS spectral analyses using the same LC-MS system. As summarized in Supplementary Table 2 and Supplementary Fig. 1A–F, the Progenesis QI predictions were confirmed by the authentic MS/MS spectral analyses. By matching the retention times and MS/MS fragmentation patterns with those of standard compounds, the ions at m/z 734.57 (Supplementary Fig. 1A) and m/z 760.58 (Supplementary Fig. 1B) were identified to be the protonated ions of PC (16:0/16:0) and PC (16:0/16:1), respectively. The retention time of ions at m/z 782.57 was close to that of other PCs, and the MS/MS fragmentation pattern matched that of PC (36:4) (Supplementary Fig. 1C). The retention time of ions at m/z 813.68 was close to the elution range for sphingomyelin (SM) under the same LC conditions, and its MS/MS fragmentation pattern matched that of SM (42:2) (Supplementary Fig. 1D). We also examined other ions (m/z 762.60 and m/z 732.55) that were abundant in the lung sample. By matching the retention times and MS/MS fragmentation patterns with those of standard compounds (Supplementary Fig. 1E), the ions at m/z 762.60 were identified to be PC (16:0/18:0). The retention time of ions at m/z 732.55 was close to that of other PCs, and the MS/MS fragmentation pattern matched that of PC (16:0/16:1) (Supplementary Fig. 1F).

We also picked up several insignificant lipids identified by the global metabolomic analysis with LC–MS and summarised them in the Supplemental Table 3. The VIP scores of these candidate lipids are low, and there is almost no difference in the average signal intensity between normal lung and lung adenocarcinoma tissues. However, we did not use standard compounds to identify these insignificant lipids.

There were significant differences between the adenocarcinoma and normal lung specimens in the relative abundances of PC (16:0/16:0) and SM (42:2), especially in the latter (P = 0.0004). The mean abundances of both lipids were higher in the normal lung specimens than the adenocarcinoma specimens. In contrast, there were no significant differences between the 2 groups in the mean abundances of PC (16:0/16:1) (P = 0.2879) and PC (36:4) (P = 0.2454) (Fig. 2A–D). As shown in Fig. 2E, the ratios of PC (16:0/16:1)/PC (16:0/16:0), PC (16:0/18:1)/PC (16:0/16:0), and PC (16:0/18:1)/PC (16:0/18:0) were significantly higher in the adenocarcinoma specimens than the normal lung specimens (P = 0.0221, P = 0.0004, and P = 0.0215, respectively).

**MALDI-IMS analysis results.** The intra-lung distribution of the various lipid species and the ratios of their abundances were examined using MALDI-IMS. The typical mass spectra of samples from adenocarcinoma and normal lung specimens are presented in Fig. 3. The samples shown in Figs 3 and 4 were collected from Patient 14 (shown in Table 1).
Figure 4A shows the different distribution of ions between the tumour region and surrounding normal lung parenchyma as revealed by haematoxylin and eosin (H&E) staining. Figure 4B shows an electron microscope image of the same area. We present MALDI-IMS images from adjacent or near-adjacent sections of ions at m/z 734.57 (PC [16:0/16:0]) in Fig. 4C and at m/z 760.58 (PC [16:0/18:1]) in Fig. 4D. Supplementary Fig. 2 shows MALDI-IMS images of ions at m/z 732.55 (PC [16:0/16:1]), m/z 762.60 (PC [16:0/18:0]), m/z 782.57 (PC [36:4]), and m/z 813.68 (SM [42:2]).

As shown in Fig. 5, the intensity ratios of PC (16:0/16:1)/PC (16:0/16:0), PC (16:0/18:1)/PC (16:0/16:0), and PC (16:0/18:1)/PC (16:0/18:0) were significantly higher (P < 0.0001) in the adenocarcinoma specimens than the normal lung specimens, which was consistent with the results from the LC-MS analysis.

The intensity ratio of PC (16:0/18:1)/PC (16:0/18:0) was significantly lower in solid predominant tumour specimens than the other subtypes (n = 8 vs 17; P = 0.0028) (Fig. 6).

Discussion

Cancer-associated metabolic processes have been the subject of numerous studies since it was discovered that cancer cells demonstrate an upregulation of glycolysis and lactate production\(^\text{19}\). Many types of cancer show increased glucose uptake and enhanced glycolytic rates, which suggests that the rapid growth of tumour cells contributes to metabolic alterations. In lung cancer, the activation of lipid metabolism has been suggested to be a hallmark of carcinogenesis\(^\text{10,12,14,20}\).

First, we performed global metabolome analysis (LC–MS) using three cases and three controls (the total sample size was 6) and identified the molecules with m/z of 734.57 (PC [16:0/16:0]) in Fig. 4C and at m/z 760.58 (PC [16:0/18:1]) in Fig. 4D. Supplementary Fig. 2 shows MALDI-IMS images of ions at m/z 732.55 (PC [16:0/16:1]), m/z 762.60 (PC [16:0/18:0]), m/z 782.57 (PC [36:4]), and m/z 813.68 (SM [42:2]).

As shown in Fig. 5, the intensity ratios of PC (16:0/16:1)/PC (16:0/16:0), PC (16:0/18:1)/PC (16:0/16:0), and PC (16:0/18:1)/PC (16:0/18:0) were significantly higher (P < 0.0001) in the adenocarcinoma specimens than the normal lung specimens, which was consistent with the results from the LC-MS analysis.

The intensity ratio of PC (16:0/18:1)/PC (16:0/18:0) was significantly lower in solid predominant tumour specimens than the other subtypes (n = 8 vs 17; P = 0.0028) (Fig. 6).

Table 1. Clinicopathological features of the patients. aDenotes patients who underwent both liquid chromatography–mass spectrometry and imaging mass spectrometry analyses. bSamples from Patient 14 were used in the histological analysis, electron microscope imaging, and liquid chromatography–mass spectrometry and imaging mass spectrometry analyses shown in Figs 3 and 4. MP = Micropapillary. Pap = Papillary. Lep = Lepidic. UICC = Union for International Cancer Control.

| Patient No. | Age | Histology | T | N | p-Stage, UICC 7th ed. | p-Stage, UICC 8th ed. | Tumour size (mm) |
|-------------|-----|-----------|---|---|---------------------|---------------------|------------------|
| 1a          | 71  | MP        | t1 | n0| IA                  | IA3                 | 22               |
| 2a          | 70  | Pap       | t1 | n0| IA                  | IA3                 | 23               |
| 3a          | 70  | Solid     | t1 | n0| IA                  | IA3                 | 29               |
| 4a          | 42  | Acinar    | t1 | n0| IA                  | IA3                 | 27               |
| 5a          | 76  | Micinous  | t2 | n0| IB                  | IA                  | 45               |
| 6a          | 76  | Pap       | t2 | n0| IB                  | IB                  | 39               |
| 7           | 66  | Acinar    | t2 | n0| IB                  | IB                  | 34               |
| 8           | 46  | Acinar    | t2 | n2| IIIA                | IIIA                | 38               |
| 9           | 73  | Lep       | t1 | n0| IA                  | IA2                 | 18               |
| 10          | 66  | Lep       | t1 | n0| IA                  | IA3                 | 22               |
| 11          | 72  | MP        | t1 | n0| IA                  | IA3                 | 24               |
| 12          | 82  | Micinous  | t1 | n0| IA                  | IA2                 | 12               |
| 13          | 65  | Micinous  | t4 | n0| IIIB                | IIIA                | 80               |
| 14a         | 64  | Pap       | t1 | n0| IA                  | IA3                 | 26               |
| 15          | 64  | Pap       | t1 | n0| IA                  | IA3                 | 25               |
| 16          | 54  | Pap       | t1 | n0| IA                  | IA2                 | 17               |
| 17          | 72  | Pap       | t1 | n0| IA                  | IA2                 | 20               |
| 18          | 60  | Pap       | t1 | n1| IIIA                | IA3                 | 27               |
| 19          | 70  | Solid     | t1 | n0| IA                  | IA2                 | 15               |
| 20          | 62  | Solid     | t1 | n0| IA                  | IA2                 | 20               |
| 21          | 75  | Solid     | t1 | n0| IA                  | IA3                 | 21               |
| 22          | 77  | Solid     | t2 | n0| IB                  | IIIA                | 43               |
| 23          | 58  | Solid     | t2 | n0| IB                  | IIIA                | 40               |
| 24          | 74  | Solid     | t1 | n1| IIIA                | IIIA                | 23               |
| 25          | 72  | Solid     | t2 | n1| IIIB                | IIIB                | 38               |

Figure 4A shows the different distribution of ions between the tumour region and surrounding normal lung parenchyma as revealed by haematoxylin and eosin (H&E) staining. Figure 4B shows an electron microscope image of the same area. We present MALDI-IMS images from adjacent or near-adjacent sections of ions at m/z 734.57 (PC [16:0/16:0]) in Fig. 4C and at m/z 760.58 (PC [16:0/18:1]) in Fig. 4D. Supplementary Fig. 2 shows MALDI-IMS images of ions at m/z 732.55 (PC [16:0/16:1]), m/z 762.60 (PC [16:0/18:0]), m/z 782.57 (PC [36:4]), and m/z 813.68 (SM [42:2]).

As shown in Fig. 5, the intensity ratios of PC (16:0/16:1)/PC (16:0/16:0), PC (16:0/18:1)/PC (16:0/16:0), and PC (16:0/18:1)/PC (16:0/18:0) were significantly higher (P < 0.0001) in the adenocarcinoma specimens than the normal lung specimens, which was consistent with the results from the LC-MS analysis.

The intensity ratio of PC (16:0/18:1)/PC (16:0/18:0) was significantly lower in solid predominant tumour specimens than the other subtypes (n = 8 vs 17; P = 0.0028) (Fig. 6).
We also found that PC (16:0/16:0) and SM (42:2) were significantly less abundant in all lung adenocarcinoma specimens than in normal lung tissue (Fig. 2A,D). Pulmonary surfactant, a complex of lipids and proteins secreted by type II alveolar cells, reduces the surface tension at the air-liquid interface17,18,21. This surfactant consists of PC, SM, and various surfactant proteins (e.g., SP-A, SP-B, SP-C, and SP-D). PC (16:0/16:0), or dipalmitoylphosphatidylcholine, is a main component of pulmonary surfactant17,18. We posit that a reduction in the number of normal type II alveolar cells in the tumour region may have contributed to the observed reduction of PC (16:0/16:0) in the adenocarcinoma specimens.

Our experiments detected a prominent difference in the abundance of SM (42:2) between adenocarcinoma and normal lung specimens (P < 0.0001). This suggests the presence of a specialized metabolic pathway for SM (42:2) in lung cancer cells. SM, which is the major sphingolipid in mammalian cells and represents one of the main lipid components of pulmonary surfactant, has also been reported to decrease in other tumour cells22. SM also has shown an anti-cancer effect in colon cancer23. Based on our findings, we believe that decreases in the abundance of PC (16:0/16:0) and SM (42:2) may have useful applications in the auxiliary diagnosis of adenocarcinoma. These 2 lipids may therefore play important roles as key lipids in cancer metabolism. On the other hand, we found no significant differences in the mean abundance of PC (16:0/18:1) (P = 0.2879) and PC (36:4) (P = 0.2454) between adenocarcinoma and normal lung specimens (Fig. 2B,C). In contrast, previous studies have reported increases in PC (16:0/18:1) in lung cancer cells10,12,14. We were unable to identify the reasons for this discrepancy, and further analyses are needed to determine if these 2 lipids have potential applications in cancer diagnoses.

The levels of monounsaturated fatty acids and monounsaturated PCs have been reported to be significantly higher than those of saturated and polyunsaturated PCs in the cancer microenvironment8–11. Therefore, our study focused on the ratios of PC (16:0/16:1)/PC (16:0/16:0), PC (16:0/18:1)/PC (16:0/16:0), and PC (16:0/18:1)/PC

| m/z   | Retention time (min) | VIP score |
|-------|----------------------|-----------|
| 734.57| 8.24                 | 23.9762   |
| 813.68| 13.51                | 19.7024   |
| 760.58| 8.51                 | 15.1571   |
| 782.57| 6.66                 | 14.1025   |

Table 2. Variable importance in projection (VIP) score of the OPLS-DA in the top four ions VIP, variable importance in projection.
5Scientific Reports | (2019) 9:8916 | https://doi.org/10.1038/s41598-019-45506-3
www.nature.com/scientificreports

Our experiments showed that these ratios were significantly higher in the lung adenocarcinoma specimens than the normal lung specimens. The detection of increases in these ratios may therefore have useful applications in the auxiliary diagnosis of cancer.

Figure 2. Box plots showing the relative abundance of each lipid (A–D) and the ratios of monounsaturated phosphatidylcholine (PC) to saturated PC (E–G) in adenocarcinoma (ADC) and normal lung (NL) specimens from 6 patients through liquid chromatography–mass spectrometry analysis. P values were calculated using Student’s t-test.

Figure 3. Typical mass spectra of samples from adenocarcinoma (A) and normal lung specimens (B). The data shown in this figure were obtained from Patient 14 in Table 1.

(16:0/18:0). Our experiments showed that these ratios were significantly higher in the lung adenocarcinoma specimens than the normal lung specimens. The detection of increases in these ratios may therefore have useful applications in the auxiliary diagnosis of cancer.
MALDI-IMS is an MS technique that facilitates the acquisition of mass spectra directly from specimens and constructs density maps of the detected ions. While conventional MS analyses require lipid extraction, MALDI-IMS does not involve the destruction of histological structures in specimens. In addition, analysts are able to compare the MALDI-IMS images with corresponding optical images. MALDI-IMS is therefore commonly used to investigate the localization of lipids in cancer specimens. In this study, we considered MALDI-IMS to be the best tool to examine lipid distribution in the adenocarcinoma specimens, which demonstrate various pathological characteristics. Similar to the results of the LC-MS analysis, the MALDI-IMS analysis found significantly higher signal intensity ratios of PC (16:0/18:1)/PC (16:0/18:0), PC (16:0/16:1)/PC (16:0/16:0), and PC (16:0/18:1)/PC (16:0/16:0) in the lung adenocarcinoma specimens than the normal lung specimens. The results from the 2 analytical approaches indicated that lung adenocarcinoma specimens have a higher expression of monounsaturated PCs than normal lung specimens. In this way, the LC-MS results were revaluated and confirmed using the MALDI-IMS analysis, which was supplemented with information on intra-lung localization of each lipid.

Figure 4. Histological image with haematoxylin and eosin staining (A), electron microscope image (B), and matrix-assisted laser desorption/ionization imaging mass spectrometry images (C, D) of adjacent or near-adjacent sections from a single patient (Patient 14 in Table 1). (C) shows an ion image of phosphatidylcholine (PC) (16:0/16:0), and Fig. 4d shows an ion image of PC (16:0/18:1). Haematoxylin and eosin staining indicated papillary adenocarcinoma in the left side of the histological image (A), and the right side was identified as normal lung tissue. PC (16:0/16:0), which was the most abundant lipid in the normal lung region, was concentrated along the alveolar wall (C). In contrast, PC (16:0/18:1), which was the most abundant lipid in the tumour region, was concentrated among the tumour cells (D). Bar: 200 μm. The boundary between the tumour tissue and the normal tissue is pointed by yellow arrow head.

Although it is said our MALDI-IMS instrument has the ability to perform MS/MS analysis, we could not get MS/MS information of MALDI-IMS in this study. Interfering noises were mixed in the background during MS/MS analysis, and it was extremely difficult to identify clear MS/MS fragmentation patterns. We could not clarify the reason why MS/MS analysis using MALDI-IMS did not work. It might be controversial whether the results of the LC–MS/MS and MALDI-IMS analyses are in perfect correspondence. However, we believe that their correspondence is highly likely because of the following: (1) We used the same specimens. (2) The observed accurate masses were identical for corresponding molecules. (3) The characteristics and abundance of the corresponding molecules are very similar. They all were quite abundant in lung specimens and very easily and strongly ionised.

Analysis of the adenocarcinoma subtypes revealed that the PC (16:0/18:1)/PC (16:0/18:0) ratio was significantly lower in solid type tumours than in the other subtypes (P = 0.0028). We suspect that this difference is influenced by enzymes that play an important role in PC synthesis. PCs are synthesized via de novo and remodelling pathways. Figure 7 shows a schematic diagram of PC development. In the remodelling pathway, monounsaturated fatty acids (palmitoleic acid [16:1] and oleic acid [18:1]) are endogenously produced from their corresponding saturated fatty acids (palmitic acid [16:0] and stearic acid [18:0]) through the action of stearoyl-CoA desaturase-1 (SCD-1), and subsequently converted into monounsaturated PC. SCD-1 is thought to play an important role in cancer progression. In addition, lyso-PC acyltransferases (LPCATs) and elongation of very long fatty
acids (ELOVLs) have also been reported to be important components of PC metabolism\textsuperscript{11,16,26,28}. LPCATs, which catalyse the reacylation of phospholipids, are particularly important in PC synthesis. ELOVL6 is a rate-limiting enzyme that catalyses the elongation reaction of palmitic acid [16:0] to stearic acid [18:0]\textsuperscript{16}. Although it is difficult to determine the reason for the different PC (16:0/18:1)/PC (16:0/18:0) ratio between solid tumours and the other subtypes, we posit that the difference may be driven by the aforementioned enzymes.

Limitations. First, there was a relatively small number of samples in this study. Specifically, the sample size for each adenocarcinoma subtype was small, and there was a bias in the number of samples in each subtype group. We also have the advanced cases in our sample, although most samples were from pathological Stage I. There may be also some individual differences of lipids metabolism among different patients. We could not clearly identify the reliability using multivariate analysis, and we did not practically validate the cross-validation or data training model in this small number of groups. Therefore, future studies should be conducted using larger sample sizes for each subtype and pathological Stage.

Second, several different key enzymes are involved in the metabolic pathways of phospholipids. As this study focused on comparing the abundance of metabolic products between normal lung and lung adenocarcinoma...
filing, datasets were obtained using MSE Technology (Waters), in which the MS and MS/MS spectra were acquired with ESI ion source (Waters). MS was performed in the electrospray ionization positive ion mode. For global lipid profiling, liquid chromatography were infused online to a Xevo G2-S Q-Tof mass spectrometer equipped with an acetonitrile and 0.1% formic acid/10 mM ammonium formate/10% acetonitrile/90% isopropanol were used as mobile phases A and B, respectively. The flow rate was set to 0.4 mL/min. The eluates from ultra-high performance liquid chromatography H-class system (Waters, Milford, MA, USA) with a binary gradient pump. 

The gradient program was as follows: 40% to 43% B in 2 min (Curve 6), 43% to 50% B in 0.1 min (Curve 1), 50% to 54% B in 9.9 min (Curve 6), 54% to 70% B in 0.1 min (Curve 1), 70% to 99% B in 5.9 min (Curve 6), 99% to 40% B in 0.1 min (Curve 6), and 40% B for 1.9 min. Mixtures of 0.1% formic acid/10 mM ammonium formate/60% acetonitrile and 0.1% formic acid/10 mM ammonium formate/10% acetonitrile/90% isopropanol were used as mobile phases A and B, respectively. The flow rate was set to 0.4 mL/min. The eluates from ultra-high performance liquid chromatography were infused online to a Xevo G2-S Q-Tof mass spectrometer equipped with an ESI ion source (Waters). MS was performed in the electrospray ionization positive ion mode. For global lipid profiling, datasets were obtained using MS^3 Technology (Waters), in which the MS and MS/MS spectra were acquired globally in a single run. Collision-induced dissociation was utilised for the authentic MS/MS spectral analyses. Datasets were acquired with precursor m/z values and fixed collision energies optimal for each compound. The optimal collision energies for each compound were determined through the stepwise screening of the voltages (from 10 to 200 V). The datasets obtained from the global lipid profiling (Six cases; pairs of 6 adenocarcinoma specimens and 6 normal lung specimens) were exported to Progenesis QI software (Nonlinear Dynamics, New Castle upon Tyne, UK) for analysis. Alignments, peak findings, relative abundance calculations, and database

Figure 7. Presumed schematic diagram of phosphatidylcholine (PC) development. Monounsaturated fatty acids are endogenously produced from the corresponding saturated fatty acids through the action of stearoyl-CoA desaturase-1 (SCD-1). Lyso-PC acyltransferase (LPCAT) may catalyse the synthesis of PC in pulmonary surfactant and play a critical role in respiratory physiology. Elongation of very long fatty acids 6 (ELOVL6) is a rate-limiting enzyme that catalyses the elongation reaction of C16:0 to C18:0.

Conclusion
The lung adenocarcinoma microenvironment is characterized by significantly higher ratios of monounsaturated PCs to saturated PCs, and the solid tumour subtype possibly had a lower ratio than the other adenocarcinoma subtypes. Despite the above limitations, we believe that our study will be important in the field of cancer metabolism.

Materials and Methods
Clinical specimens. Samples of lung adenocarcinoma and normal lung tissue were obtained from patients who underwent lung cancer surgery in the Department of Thoracic Surgery, Kyoto University Hospital (Kyoto, Japan) between January 2013 and December 2014. All samples were collected in accordance with ethical guidelines, and all patients were approached based on approved ethical guidelines. Written informed consent was obtained from all patients prior to inclusion in the study (Authorization Number: R0097). A total of 25 patients who underwent pulmonary resection for lung adenocarcinoma with curative intent were included in analysis. Twenty-five patients were included to ensure that each invasive adenocarcinoma subtype (lepidic, acinar, papillary, micropapillary, solid, and mucinous) was represented for the pathological diagnosis.

Adenocarcinoma tissue and normal lung specimens (each several square millimetres in size) were harvested from these patients and flash frozen in liquid nitrogen. The specimens were stored at −80 °C until used in the experiments. Normal lung specimens were harvested from parts of the lung distant from the tumour within the same lobe. All H&E-stained slides were evaluated by a pathologist and a thoracic surgeon to determine the subtype of adenocarcinoma. These slides were used as a guide for MALDI-IMS analysis.

LC-MS analysis. The frozen specimens were excised using a disposable scalpel and weighed after freezing. Total lipids were extracted using a commercial lipid extraction kit (BioVision Inc, Milpitas, CA, USA). The volume of extraction solution was determined according to the measured weight of each specimen. The volume-matched lipid extracts for each specimen were aliquoted and dried under nitrogen before being reconstituted in a mixture of 50% isopropanol/25% acetonitrile/25% water. The reconstituted samples were separated using an ultra-high performance liquid chromatography H-class system (Waters, Milford, MA, USA) with a binary gradient pump.

The gradient program was as follows: 40% to 43% B in 2 min (Curve 6), 43% to 50% B in 0.1 min (Curve 1), 50% to 54% B in 9.9 min (Curve 6), 54% to 70% B in 0.1 min (Curve 1), 70% to 99% B in 5.9 min (Curve 6), 99% to 40% B in 0.1 min (Curve 6), and 40% B for 1.9 min. Mixtures of 0.1% formic acid/10 mM ammonium formate/60% acetonitrile and 0.1% formic acid/10 mM ammonium formate/10% acetonitrile/90% isopropanol were used as mobile phases A and B, respectively. The flow rate was set to 0.4 mL/min. The eluates from ultra-high performance liquid chromatography were infused online to a Xevo G2-S Q-Tof mass spectrometer equipped with an ESI ion source (Waters). MS was performed in the electrospray ionization positive ion mode. For global lipid profiling, datasets were obtained using MS^3 Technology (Waters), in which the MS and MS/MS spectra were acquired globally in a single run. Collision-induced dissociation was utilised for the authentic MS/MS spectral analyses. Datasets were acquired with precursor m/z values and fixed collision energies optimal for each compound. The optimal collision energies for each compound were determined through the stepwise screening of the voltages (from 10 to 200 V). The datasets obtained from the global lipid profiling (Six cases; pairs of 6 adenocarcinoma specimens and 6 normal lung specimens) were exported to Progenesis QI software (Nonlinear Dynamics, New Castle upon Tyne, UK) for analysis. Alignments, peak findings, relative abundance calculations, and database
searches of LIPID MAPS [https://www.lipidmaps.org/] and the Human Metabolome Database [http://www.hmdb.ca/] were performed using Progenesis QI. The peak areas for each compound were normalized to total compound intensity and examined as relative abundances. The normalized relative abundances of all compounds were exported to EZinfo (Umetrics, Umeå, Sweden). OPLS-DA was performed using EZinfo, and the obtained result was converted to the S-plot format. The reliability of compound identification by Progenesis QI was revaluated using the authentic MS/MS spectral analyses in which standard compounds (if commercially available) were measured by the same LC-MS system with appropriate modifications to the MS settings. Lipid standards (PC [16:0/16:0], PE [16:0/18:1], and PC [16:0/18:0]) were purchased from Avanti Polar Lipids (Alabaster, AL, USA).

**MALDI-IMS analysis.** The frozen specimens were sectioned on a cryostat (CM1850; Leica, Wetzler, Germany) at −20 °C. Cryosections of 8-μm thickness were mounted onto indium–tin oxide slides, and every other section was mounted onto common glass slides for H&E staining. The slides for adenocarcinoma specimens and normal lung specimens were prepared separately. This process was entrusted to the Kyoto Nutrition Pathology Laboratory. Each section was coated with 9-aminoacridine hemihydrate (Acros Organics, Geel, Belgium), which served as the matrix for MALDI-IMS. The slides were anchored in a vacuum deposition chamber (SVC-700TM/700-2; Sanyu Electron, Tokyo, Japan) and mechanically coated with 9-aminoacridine hemihydrate evaporated at −20 °C. The time required for this vapor deposition process was 8 min.

High-resolution MALDI-IMS analysis was performed on a high-resolution microscopic imaging mass spectrometer (RK27-4050C; Shimadzu, Kyoto, Japan; the prototype model of IMScope) equipped with a 355-nm Nd:YAG laser. MS data were acquired in positive ion mode in the 500.0–1200.0 m/z range using an external calibration method. Each region of interest was determined from the microscopic view of the slides and referring to the adjacent H&E-stained sections. We selected regions of interest that were mainly occupied by one subtype (>50%); mass spectra were obtained at a spatial resolution of 10 μm.

The spectra and mean signal intensities of the regions of interest were analysed, and the MS data were normalized to the total ion current to eliminate variations in ionization efficiency using the Imaging MS Solution™ program (Shimadzu).

**Statistical analysis.** The difference in signal intensities or signal intensity ratios were compared using Student’s t-test. Statistical analyses were performed using JMP version 12.0 (SAS, Cary, NC, USA), and P values below 0.05 were considered statistically significant.

**Ethical statement.** All study protocols were approved by the Ethics Committee for Clinical Research, Kyoto University Hospital (Approval number: R369).

**References**

1. Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136, E359–386, https://doi.org/10.1002/ijc.29210 (2015).

2. Herbst, R. S. et al. Lung Cancer. N. Engl. J. Med. 359, 1367–1380, https://doi.org/10.1056/NEJMra0802714 (2008).

3. Travis, W. D. et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6, 244–285, https://doi.org/10.1097/JTO.0b013e3182062221 (2011).

4. Yoshizawa, A. et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 24, 653–664, https://doi.org/10.1038/modpathol.2010.232 (2011).

5. Schulze, A. & Harris, A. L. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 491, 364–373, https://doi.org/10.1038/nature11706 (2012).

6. Menendez, J. A. & Lupu, R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nature Reviews Cancer 7, 763–777, https://doi.org/10.1038/nrc2222 (2007).

7. Zaidi, N. et al. Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. Prog Lipid Res 52, 585–589, https://doi.org/10.1016/j.plipres.2013.08.005 (2013).

8. Ide, Y. et al. Human breast cancer tissues contain abundant phosphatidylcholine(36ratio1) with high stearoyl-CoA desaturase-1 expression. PLoS One 8, e61204, https://doi.org/10.1371/journal.pone.0061204 (2013).

9. Roonga, U. V. et al. Cancer cell dependence on unsaturated fatty acids implicates stearoyl-CoA desaturase as a target for cancer therapy. Mol Cancer Res 9, 1551–1561, https://doi.org/10.1158/1541-7786.MCR-11-0126 (2011).

10. Guo, S., Wang, Y., Zhou, D. & Li, Z. Significantly increased monounsaturated lipids relative to polyunsaturated lipids in six types of cancer microenvironment are observed by mass spectrometry imaging. Sci Rep 4, 5959, https://doi.org/10.1038/srep05959 (2014).

11. Kurabe, N. et al. Accumulated phosphatidylcholine (16:0/16:1) in human colorectal cancer: possible involvement of LPCAT4. Cancer Sci 104, 1295–1302, https://doi.org/10.1111/cas.12221 (2013).

12. Marien, E. et al. Non-small cell lung cancer is characterized by dramatic changes in phospholipid profiles. Int J Cancer 137, 1539–1548, https://doi.org/10.1002/ijc.29591 (2015).

13. He, M., Guo, S., Ren, J. & Li, Z. In Situ Characterizing Membrane Lipid Phenotype of Human Lung Cancer Cell Lines Using Mass Spectrometry Profiling. J Cancer 7, 810–816, https://doi.org/10.7150/jca.14310 (2016).

14. Lee, G. K. et al. Lipid MALDI profile classifies non-small cell lung cancers according to the histologic type. Lung Cancer 76, 197–203, https://doi.org/10.1016/j.lungcan.2011.06.016 (2012).

15. Merino Salvador, M. et al. Lipid metabolism and lung cancer. Crit Rev Oncol Hematol 112, 31–40, https://doi.org/10.1016/j.critrevonc.2017.02.001 (2017).

16. Eya Marien1, M. M. et al. Phospholipid profiling identifies acyl chain elongation as a ubiquitous trait and potential target for the treatment of lung squamous cell carcinoma. Oncotarget 8, 15623–15640, https://doi.org/10.18632/oncotarget.8444 (2016).

17. Chen, X., Hyatt, R. A., Muscinski, M. L., Mason, R. J. & Shannon, J. M. Identification and characterization of a lysophosphatidylcholine acyltransferase in alveolar type II cells. Proc Natl Acad Sci USA 103, 11724–11729, https://doi.org/10.1073/pnas.0604946103 (2006).

18. Kurabe, N. et al. Visualization of phosphatidylcholine (16:0/16:0) in type II alveolar epithelial cells in the human lung using imaging mass spectrometry. Pathol Int 65, 195–200, https://doi.org/10.1111/pin.12050 (2015).

19. Warburg, O. On the origin of cancer cells. Science 123, 309–314 (1956).
20. Xie, W., Gao, D., Jin, F., Jiang, Y. & Liu, H. Study of Phospholipids in Single Cells Using an Integrated Microfluidic Device Combined with Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry. Anal Chem 87, 7052–7059, https://doi.org/10.1021/acs.analchem.5b00010 (2015).

21. Nakanishi, H. et al. Cloning and characterization of mouse lung-type acyl-CoA:lysophosphatidylcholine acyltransferase 1 (LPCAT1). Expression in alveolar type II cells and possible involvement in surfactant production. J Biol Chem 281, 20140–20147, https://doi.org/10.1074/jbc.M600225200 (2006).

22. Barcelo-Coblijn, G. et al. Sphingomyelin and sphingomyelin synthase (SMS) in the malignant transformation of glioma cells and in 2-hydroxyoleic acid therapy. Proc Natl Acad Sci USA 108, 19569–19574, https://doi.org/10.1073/pnas.1115484108 (2011).

23. Lemonnier, L. A. et al. Sphingomyelin in the suppression of colon tumors: prevention versus intervention. Archives of Biochemistry and Biophysics 419, 129–138, https://doi.org/10.1016/j.abb.2003.08.023 (2003).

24. Kawashima, M. et al. High-resolution imaging mass spectrometry reveals detailed spatial distribution of phosphatidylinositolos in human breast cancer. Cancer Sci 104, 1372–1379, https://doi.org/10.1111/cas.12229 (2013).

25. Goto, T. et al. The expression profile of phosphatidylinositol in high spatial resolution imaging mass spectrometry as a potential biomarker for prostate cancer. PLoS One 9, e90242, https://doi.org/10.1371/journal.pone.0090242 (2014).

26. Harayama, T. et al. Lysophospholipid acyltransferases mediate phosphatidylcholine diversification to achieve the physical properties required in vivo. Cell Metab 20, 293–306, https://doi.org/10.1016/j.cmet.2015.05.019 (2014).

27. Huang, J et al. SCD1 is associated with tumor promotion, late stage and poor survival in lung adenocarcinoma. Oncotarget, Vol. 7, No. 26 (May 19, 2016).

28. Shindou, H. & Shimizu, T. Acyl-CoA:lysophospholipid acyltransferases. J Biol Chem 284, 1–5, https://doi.org/10.1074/jbc.R800046200 (2009).

Acknowledgements
We would like to express our appreciation to Mamoru Honda of Shimadzu Techno-Research, Inc. (Kyoto, Japan) for providing guidance for IMS.

Author Contributions
Yusuke Muranishi and Toshihiko Sato designed the study, contributed to the analysis and interpretation of MALDI-IMS data, and wrote the initial draft of the manuscript. Shinji Ito and Junko Satoh contributed to the analysis and interpretation of LC-MS data, and assisted in the preparation of the manuscript. Akihiko Yoshizawa performed the pathological evaluation of the adenocarcinoma specimens. All other authors contributed to data collection and interpretation, and critically reviewed the manuscript. All authors approved the final version of the manuscript, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-45506-3.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019